StockData

Eton Pharmaceuticals vs Zevra Therapeutics

ETON and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ETON and ZVRA compare

Eton Pharmaceuticals is the larger company, worth 3.3 times as much as Zevra Therapeutics ($1.8B against $558M).

On earnings, Zevra Therapeutics is cheaper: it trades at 10.1× trailing earnings, against 163× for Eton Pharmaceuticals.

Zevra Therapeutics grew revenue faster over the last twelve months (119% versus 81.5% for Eton Pharmaceuticals).

Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with 12.0% at Eton Pharmaceuticals.

Zevra Therapeutics scores higher on the StockData Score (15 against 10 for Eton Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricETONZVRA
Size and price
Market cap$1.8B$558M
Share price$63.65$9.40
Change, 1 year276%5.9%
Change, 5 years1408%16.8%
Beta (5Y)−0.441.16
Employees4461
StockData Score
Total score1015 (better)
Valuation score03 (better)
Growth score33
Performance score4 (better)3
Health score36 (better)
Dividend score00
Valuation
P/E163×10.1× (better)
P/S17.2×4.1× (better)
P/B39.1×2.6× (better)
EV/EBITDA87.3×4.0× (better)
P/FCF123×17.1× (better)
FCF yield0.81%5.8% (better)
Fair value$10.20$23.57
Margin of safety−524%60.1% (better)
Growth
Revenue growth (TTM)81.5%119% (better)
Revenue growth, 5Y average360% (better)51.6%
Net income growth (TTM)–2104%
Profitability
Gross margin57.9%95.5% (better)
Operating margin15.4%60.5% (better)
Net margin12.0%42.8% (better)
FCF margin14.0%24.0% (better)
Return on equity36.0% (better)34.8%
Return on invested capital42.5%–
Financial health
Debt / equity0.60 (better)0.00
Net debt / EBITDA0.05 (better)−2.64
Interest coverage3.6×14.4× (better)
Current ratio1.525.17 (better)
Altman Z-score16.19 (better)4.35
Piotroski F-score46 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.0%78.5%
Held by insiders5.6%1.2%
Insider net buying, 12 months−$35.0M−$2.5M (better)
Short interest, % of float7.4%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.